Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 1.00 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 0.96 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.64 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.59 |
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.48 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.43 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.40 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1998656 | 1.00 | ACHE (1.00) | ACHEPRKCIPOLBKDM4EMEN1 | |
| SCHEMBL111109 | 0.98 | PRKCI (1.00) | ACHEPRKCIPOLBKDM4EMEN1 | |
| SCHEMBL29565648 | 0.98 | PRKCI (1.00) | ACHEPRKCIPOLBKDM4EMEN1 | |
| SCHEMBL5270782 | 0.91 | PRKCI (0.86) | ACHEPRKCIPOLBKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL29355056 | 0.85 | ACHE (0.74) | ACHEPRKCIPOLBKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL3336998 | 0.85 | ACHE (0.74) | ACHEPRKCIPOLBKDM4EMEN1 | |
| SCHEMBL7566226 | 0.84 | PRKCI (0.73) | ACHEPRKCIPOLBKDM4EMEN1 | |
| SCHEMBL5190111 | 0.84 | PRKCI (0.74) | ACHEPRKCIPOLBKDM4EMEN1 | |
| SCHEMBL1498028 | 0.83 | PRKCI (0.73) | ACHEPRKCIPOLBKDM4EMEN1 | |
| SCHEMBL28837441 | 0.83 | PRKCI (0.73) | ACHEPRKCIPOLBKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120202243-A | Thermosetting resin composition, cured film, substrate, and electronic component | 捷恩智株式会社 | 2025-06-24 | — | — | CN | disclosed |
| EP-1885486-B1 | AFFINITY ADSORBENTS FOR FACTOR VIII AND VON WILLEBRAND'S FACTOR | PROMETIC BIOSCIENCES LTD (GB) | 2016-03-23 | — | — | EP | disclosed |
| US-7960182-B2 | Affinity adsorbents for Factor VIII and von Willebrand's Factor | PROMETIC BIOSCIENCES LTD. (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20090275141-A1 | Affinity Adsorbents for Factor VIII and Von Willebrand's Factor | DEPARTMENT OF ECONOMIC DEVELOPMENT (IM) | 2009-11-05 | — | — | US | disclosed |
| EP-1885486-A1 | AFFINITY ADSORBENTS FOR FACTOR VIII AND VON WILLEBRAND'S FACTOR | Prometic Biosciences Ltd (GB) | 2008-02-13 | — | — | EP | disclosed |
| US-7214700-B2 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | SUGEN INC. (US) | 2007-05-08 | — | — | US | disclosed |
| WO-2006120427-A1 | AFFINITY ADSORBENTS FOR FACTOR VIII AND VON WILLEBRAND'S FACTOR | PROMETIC BIOSCIENCES LTD. (GB) | 2006-11-16 | — | — | WO | disclosed |
| US-20040039196-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | SUGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| US-20030216462-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | SUGEN, INC. | 2003-11-20 | — | — | US | disclosed |
| EP-1299355-A2 | (2-OXINDOL-3-YLIDENYL)ACETIC ACID DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020028828-A1 | (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors | SUGEN, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001083450-A2 | (2-OXINDOL-3-YLIDENYL)ACETIC ACID DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028828-A1 | (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors | MAPKAPK2, MAPKAPK3, MAP3K2 | ACHE 3714/4885PRKCI 23/4885CACNA1B 3573/4885 |
| US-20040039196-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | MAPKAPK2, MAPKAPK3, MAP3K2 | ACHE 3714/4885PRKCI 23/4885CACNA1B 3573/4885 |
| US-20030216462-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | MAPKAPK2, MAPKAPK3, MAP3K2 | ACHE 3714/4885PRKCI 23/4885CACNA1B 3573/4885 |
| US-20090275141-A1 | Affinity Adsorbents for Factor VIII and Von Willebrand's Factor | F8, F13B, F12 | ACHE 4873/4885PRKCI 2062/4885CACNA1B 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.